Retinoic acid receptor alpha

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

BenevolentAI: Shareholder Letter December 2023

Retrieved on: 
Thursday, December 28, 2023
Technology, Research, Finance, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Knowledge, Biology, Drug, Conference, Culture, Merck Group, Drug discovery, Medicine, ALS, AstraZeneca, Business, Data, UC, Retinoic acid receptor alpha, PDE10, AI, Business development, ID, Glioblastoma, Food, SAD, Merck, GBM, Growth, Benchmarking, Patient, Safety, Benevolence, Acceleration, Heart failure, Neurology, Ulcerative colitis, Pharmaceutical industry

Despite 2023 being a challenging year and a transition period for BenevolentAI, we have made significant progress in executing our strategic plan.

Key Points: 
  • Despite 2023 being a challenging year and a transition period for BenevolentAI, we have made significant progress in executing our strategic plan.
  • We were pleased with the signing of the new strategic collaboration with Merck KGaA in September.
  • We also introduced a new state-of-the-art target prediction methodology, which continues to enhance our previous target prediction fleet and target explanations.
  • As announced in our interim results announcement in September, we expect that headcount will be around 260 employees at the end of 2023.

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Retrieved on: 
Wednesday, December 6, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, Aplastic anemia, ID, Azacitidine, Safety, CRi, Aes, Acute myeloid leukemia, Russell R. Dohner, Patient, MRD, Hematology, ELN, Bone marrow, University, MD, RARA, Survival, AML, Doctor of Philosophy, Consistency, Șaeș, Retinoic acid receptor alpha, Venetoclax, Pharmaceutical industry, Nursing, Health insurance, Syros

“These data highlight the potential of tamibarotene to be a cornerstone therapy for newly diagnosed, unfit AML patients with RARA overexpression, further demonstrating its differentiated product profile and validating our biologically targeted approach,” said David A. Roth, M.D., Chief Medical Officer of Syros. “These results -- the first from a randomized, controlled study -- demonstrate the potential impact of adding tamibarotene to the standard-of-care, venetoclax and azacitidine and, importantly, are consistent with prior experience. Across multiple clinical trials, we have observed tamibarotene’s ability to rapidly deliver clinically relevant activity, with a well-tolerated safety profile, including in a combination setting. We look forward to advancing our comprehensive clinical development program for tamibarotene, with additional data from SELECT-AML-1 and pivotal complete response data from our SELECT-MDS-1 trial in higher-risk myelodysplastic syndrome with RARA overexpression expected next year, as we work to deliver profound benefit to patients with hematologic malignancies.”

Key Points: 
  • “These results -- the first from a randomized, controlled study -- demonstrate the potential impact of adding tamibarotene to the standard-of-care, venetoclax and azacitidine and, importantly, are consistent with prior experience.
  • Across multiple clinical trials, we have observed tamibarotene’s ability to rapidly deliver clinically relevant activity, with a well-tolerated safety profile, including in a combination setting.
  • The trial is also evaluating the triplet regimen as a salvage strategy in patients in the control arm who do not respond to venetoclax and azacitidine.
  • Syros is also evaluating tamibarotene in combination with azacitidine in the SELECT-MDS-1 Phase 3 clinical trial in newly diagnosed higher-risk myelodysplastic syndrome patients with RARA gene overexpression.

BenevolentAI: Interim Results for the Six Months Ended 30 June 2023

Retrieved on: 
Thursday, September 21, 2023
Technology, Research, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Knowledge, Acceleration, Serum response factor, Katherine, Interim, Chronic kidney disease, Normalization, ALS, GBM, Retinoic acid receptor alpha, Sustainability Accounting Standards Board, PDE10, Sutro Biopharma, Dragon (magazine), Glioblastoma, Benevolence, AstraZeneca, Ulcerative colitis, BAI, Nouvelle AI, Euronext, UC, SLS, Euronext Amsterdam, Drug discovery, Heart failure, Merck, AI, IPF, CKD, Neurology, Idiopathic pulmonary fibrosis, Success, Conference, Pharmaceutical industry, Management, Sales, Medical device, Cryptocurrency, IND

BenevolentAI (Euronext Amsterdam: BAI) (“BenevolentAI” or the “Company” or the “Group”), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2023.

Key Points: 
  • BenevolentAI (Euronext Amsterdam: BAI) (“BenevolentAI” or the “Company” or the “Group”), a leader in applying advanced AI to accelerate biopharma drug discovery, announces its unaudited interim results for the six months ended 30 June 2023.
  • We committed in May to right-sizing the business which has resulted in an extension of our cash runway to at least mid-2025.
  • In particular, I want to thank Joanna for her commitment over the last five years to build the business into what it is today.
  • Operating cash flow before changes in working capital reduced by 22% from £48.4 million (H1 2022) to £37.9 million.

Syros Acquires Clinical-Stage Drug Candidate for Acute Promyelocytic Leukemia, Expanding Its Pipeline of Targeted Therapies for Hematologic Malignancies

Retrieved on: 
Saturday, December 5, 2020
Research, Genetics, Clinical trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Leukemia, Retinoic acid receptor alpha, Acute myeloid leukemia, Acute Promyelocytic Leukemia, Syros Pharmaceuticals

Its rare to talk about cures in cancer, said Nancy Simonian, M.D., Chief Executive Officer of Syros.

Key Points: 
  • Its rare to talk about cures in cancer, said Nancy Simonian, M.D., Chief Executive Officer of Syros.
  • SY-2101 is in development for the treatment of APL, a subtype of acute myeloid leukemia (AML) defined by a fusion of the RARA and PML genes.
  • If successful, Syros believes it could file a New Drug Application (NDA) with the FDA in 2024.
  • A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .